New York, USA – March 24, 2021 – CD Genomics is one of the leaders in providing genomic research services. The company is devoted to supporting pharmaceutical and biotech companies as well as academia and government agencies. Since the past decade, CD Genomics continues to upgrade its comprehensive sequencing services and support different research fields. The company has developed multiple professional platforms focusing on microbiology, disease research, and RNA.
RNA sequencing can not only sort and classify gene expressions but also compare gene expressions. Due to the rapid development of sequencing and related technologies, RNA can be explored from every aspect, including alternative RNA splicing, post-transcriptional modifications, gene fusion, gene mutations, SNPs, and gene expression and regulation. RNA sequencing can detect total RNA, mRNA, and small RNA, as well as determine the boundaries of exons/introns.
Researchers from Biodonostia Health Research Institute, Spain, revealed specific circRNAs and linear RNAs as biomarkers from patients with lipid-specific oligoclonal IgM bands. “The presence of anti-myelin lipid-specific oligoclonal IgM bands (LS-OCMBs) has been defined as an accurate predictor of an aggressive evolution of multiple sclerosis. However, the detection of this biomarker is performed in cerebrospinal fluid, a quite invasive liquid biopsy. In the present study we aimed at studying the expression profile of miRNA, snoRNA, circRNA, and linear RNA in peripheral blood mononuclear cells (PBMCs) from patients with lipid-specific oligoclonal IgM band characterization,” said one researcher from the institute, “Our cooperation with CD Genomics was delightful. Their whole-transcriptome analysis provided a lot of help for this research.”
More than 70% of the scientists in CD Genomics hold a Ph.D. or Master’s degree, all with extensive experience in microbial genomics. CD Genomics adopts an optimized workflow, efficiently providing both next-generation sequencing and long-read sequencing coupled with a cloud-based platform for bioinformatics analysis.
“CD Genomics has already updated the technology platforms to mainstream next-generation sequencing, third-generation sequencing, microarray, and LC-MS/MS instruments,” said Dr. Charlie of CD Genomics, “we will use the most advanced technology and the most appropriate method to solve the most practical problems for our clients.”
CD Genomics provides comprehensive RNA solutions that include:
• Coding RNA Sequencing
• Non-Coding RNA Sequencing
• Epitranscriptomic Profiling
• Biofluid Profiling
• Mass Spectrometry-Based RNA Profiling
About CD Genomics
Founded in New York in 2004, CD Genomics has become one of the top providers in genomic research, providing reliable services to pharmaceutical and biotech companies as well as academia and government agencies. CD Genomics – RNA Solutions platform offers services for revolutionizing RNA studies, targeting both coding and non-coding RNAs of different physiological functions. Our dedicated scientists are always ready to help researchers detect various types of RNA via an integrative approach.